Pfizer presents split views on recovery timing
Pfizer's heavy upcoming patent cliff offers a high dividend yield for patient investors, though fundamental revenue growth may remain depressed until 2029.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.